It has been found that NR5A2 can accelerate the development of intestinal tumors through regulating cell cycle and inflammation (Petruzzelli et al., 2016) and promote the invasive ability of breast cancer cells via changing actin cytoskeleton or reducing the transcription of cyclin‐dependent kinase inhibitors independent of ERα and p53 state (Bianco et al., 2015; Chand et al., 2010). This evidence concerns the gene NR5A2 and breast carcinoma.